Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...

Updates on the Treatment of Colorectal Cancer


Description:
This activity is intended to educate pharmacists on the novel advancements in the treatment of colorectal cancer. This presentation will encompass changes/updates to traditional chemotherapy regimens, new biomarker testing required for existing therapies, and new drug approvals. The primary literature, evidence based guidelines, and clinical pearls of these new treatments will be discussed.
 
Objectives:
1. Examine recent biotherapy and biomarker updates in the treatment of colorectal cancer.
2. Review recent chemotherapy updates in the treatment of colorectal cancer.
3. Integrate considerations influencing decisions in the treatment of colorectal cancer.
 
Activity Number:
0280-0000-16-079-H01-P
 
This recorded activity is a based on a live program that was offered on October 15, 2016 in Burlington, MA.  
Participants who received credit for the live program should not claim credit for this web based presentation.
 
System Requirements for Participants:
Operating system:  Windows XP, Vista or 7  MAC OS X  Latest Version of Adobe Reader
Browser Internet Explorer 8.0 or above  Google Chrome 16.0 or above  Firefox 7.0 or above  Safari 5.0 or above
 

Fee

$0.00

CE Hours

1.00

CE Units

0.100

Activity Type

  • Application Based

Target Audience(s)

  • Pharmacists

Accreditation(s)

Accreditation Council for Pharmacy Education
American Health Resources is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education

Requirements for CE Credit

  • Complete the pre-test
  • Review the content of this activity
  • Successfully complete the post-test with a score of 80% or higher 
  • Complete the activity evaluation
Continuing pharmacy education credit is automatically reported to CPE Monitor once the post-test & evaluation is completed.
 
Pharmacists - Be sure your profile has been updated with your NAPB e-profile # and birth date information BEFORE completing the online evaluation, or your credits will NOT be reported.

Support/Credits

Discloures:
The presenter is Jane E. Rogers, PharmD, BCOP; Clinical Pharmacy Specialist, Gastrointestinal Medical Oncology, U. of Texas MD Anderson Cancer Center, Houston TX 
Dr. Rogers does not have any relevant financial relationships with any commercial interests 
     
The reviewer is Zaven Norigian, PharmD, BCOP; Pharmacy Clinical Specialist, Oncology, Lahey Clinic
Department of Pharmacy, Burlington, Massachusetts
Dr. Norigian is on the speaker’s bureau of Merck and is also on the advisory boards of Amgen, BMS, Eisai, Lilly, Pfizer and Taiho
 
Support for This Activity:
Grant support for this activity was received by Taiho Oncology, Inc.
This activity is supported by the Association of Community Cancer Centers (ACCC).
 
American Health Resources assesses conflict of interest with its instructors, reviewers and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are resolved by American Health Resources for fair balance and scientific objectivity.
 
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  American Health Resources does not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of American Health Resources.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

 

 

 

This activity is intended to educate pharmacists on the novel advancements in the treatment of colorectal cancer. This presentation will encompass changes/updates to traditional chemotherapy regimens, new biomarker testing required for existing therapies, and new drug approvals. The primary literature, evidence based guidelines, and clinical pearls of these new treatments will be discussed.
 

Objectives

  • Examine recent biotherapy and biomarker updates in the treatment of colorectal cancer.
  • Review recent chemotherapy updates in the treatment of colorectal cancer.
  • Integrate considerations influencing decisions in the treatment of colorectal cancer.

Speaker(s)/Author(s)

Jane E. Rogers, PharmD, BCOP picture

Jane E. Rogers, PharmD, BCOP
Clinical Pharmacy Specialist, Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center


Brief Bio : Jane Rogers is currently working as a Clinical Pharmacy Specialist at the University of Texas M.D. Anderson Cancer Center in Houston, TX. Dr. Rogers received her Doctor of Pharmacy degree in 2008 at West Virginia University-School of Pharmacy in Morgantown, WV. She went on to complete an ASHP-Accredited Pharmacy Practice Residency at West Virginia University Hospitals in Morgantown, WV, followed by an ASHP-Accredited Pharmacy Oncology Residency at the University of Texas M.D. Anderson Cancer Center in Houston, TX in 2009 and 2010 respectively. She is board certified in oncology pharmacy and currently works in the Gastrointestinal Medical Oncology Clinic at the University of Texas M.D. Anderson Cancer Center in Houston, TX. Dr. Rogers has experience in mentoring and educating on the topic of gastrointestinal cancers and aspects of oncology pharmacy to many members of the healthcare team.

Activity Number

0280-0000-16-079-H01-P

Release Date: Nov 4, 2016
Credit Expiration Date: Nov 2, 2018

CE Hours

1.00